CRT-P Versus CRT-D: A Match-Up Likely Never To Be Seen – NEJM Editoral
This article was originally published in The Gray Sheet
Executive Summary
Cardiac resynchronization with cardioverter defibrillation devices (CRT-D) will continue to be used more often than CRT-alone, even though the latter option may actually be better for some heart failure patients, according to John Jarcho, MD, Brigham & Women's Hospital, Boston
You may also be interested in...
Physicians Continue To Debate Key Differences Between ICDs, Pacemakers
The debate over the clinical efficacy and cost-effectiveness of cardiac resynchronization therapy with cardioverter defibrillation (CRT-D) versus CRT-alone (CRT-P) raged on March 12 at the American College of Cardiology's annual conference in Atlanta
Physicians Continue To Debate Key Differences Between ICDs, Pacemakers
The debate over the clinical efficacy and cost-effectiveness of cardiac resynchronization therapy with cardioverter defibrillation (CRT-D) versus CRT-alone (CRT-P) raged on March 12 at the American College of Cardiology's annual conference in Atlanta
CRT-D Cost-Effectiveness Disputed; JACC Editorial Says More Studies Needed
Additional head-to-head trials are necessary to assess whether the benefit of cardiac resynchronization therapy with defibrillation (CRT-D) justifies its high cost, according to Mark Hlatky, MD, Stanford University